Scientific Journal Certified with the International Standard ISO 9001:2015 - SGS

World Health Journal - Professionals On Line ISSNe: 2961-2020

Comorbidities of Diabetes Mellitus Type 2: A Comprehensive Analysis
New submissions

PDF (Spanish)


Type 2 diabetes mellitus

How to Cite

Comorbidities of Diabetes Mellitus Type 2: A Comprehensive Analysis. (2023). World Health Journal, 4(1), 48-51.


This study focuses on investigating the comorbidities associated with type 2 diabetes mellitus (DM2), using a systematic literature review methodology to identify significant connections. The findings highlight consistent links between DM2 and cardiovascular disease, renal complications, neuropathies, retinopathies, and psychological disorders. The need for a multidisciplinary clinical approach to comprehensively address these comorbidities is underscored. The conclusion emphasizes the inherent complexity of DM2 comorbidities, advocating preventive approaches and holistic treatments to improve clinical outcomes and quality of life of patients, despite the inherent limitations of the study. This work contributes to the understanding of the interrelationships between DM2 and its comorbidities, highlighting the importance of integrated interventions in the care of these patients.

PDF (Spanish)


Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, et al. Comprehensive management of cardiovascular risk factors for Adults With Type 2 diabetes: A scientific statement from the American Heart Association. Circulation [Internet]. 2022 [citado el 19 de enero de 2024];145(9). Disponible en:

Dugani SB, Mielke MM, Vella A. Burden and management of type 2 diabetes in rural United States. Diabetes Metab Res Rev [Internet]. 2021 [citado el 19 de enero de 2024];37(5). Disponible en:

Steinbrenner H, Duntas LH, Rayman MP. The role of selenium in type-2 diabetes mellitus and its metabolic comorbidities. Redox Biol [Internet]. 2022 [citado el 19 de enero de 2024];50(102236):102236. Disponible en:

Mastrototaro L, Roden M. Insulin resistance and insulin sensitizing agents. Metabolism [Internet]. 2021 [citado el 19 de enero de 2024];125(154892):154892. Disponible en:

Kirwan JP, Courcoulas AP, Cummings DE, Goldfine AB, Kashyap SR, Simonson DC, et al. Diabetes remission in the Alliance of Randomized Trials of Medicine versus Metabolic Surgery in type 2 diabetes (ARMMS-T2D). Diabetes Care [Internet]. 2022 [citado el 19 de enero de 2024];45(7):1574–83. Disponible en:

Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: Findings from the Look AHEAD study. J Am Heart Assoc [Internet]. 2021 [citado el 19 de enero de 2024];10(7). Disponible en:

Ikegami H, Hiromine Y, Noso S. Insulin‐dependent diabetes mellitus in older adults: Current status and future prospects. Geriatr Gerontol Int [Internet]. 2022 [citado el 19 de enero de 2024];22(8):549–53. Disponible en:

Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne) [Internet]. 2022 [citado el 19 de enero de 2024];13. Disponible en:

Bouchi R, Sugiyama T, Goto A, Imai K, Ihana-Sugiyama N, Ohsugi M, et al. Retrospective nationwide study on the trends in first‐line antidiabetic medication for patients with type 2 diabetes in Japan. J Diabetes Investig [Internet]. 2022 [citado el 19 de enero de 2024];13(2):280–91. Disponible en:

Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. Nat Rev Endocrinol [Internet]. 2022 [citado el 19 de enero de 2024];18(9):525–39. Disponible en:

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Alis Beatriz Chauca Arce